The market for Cardiac Resynchronization Therapy (CRT) is witnessing a surge in demand due to the escalating occurrence of heart failure worldwide. As the aging population increases and way of life factors contribute to cardiovascular illnesses, the need for powerful cardiac interventions, inclusive of CRT, is on the rise. Growing attention to cardiac fitness, coupled with stepped-forward diagnostic abilities, is contributing to an early analysis of coronary heart situations. This, in turn, is driving the demand for CRT as a vital therapeutic option for handling diverse cardiac problems, having a tremendous effect on market developments. The fashion toward miniaturization in scientific devices is influencing the CRT market, leading to the improvement of smaller and extra implant-friendly gadgets. This shift no longer best improves affected person consolation but also expands the eligible patient populace by accommodating people previously taken into consideration as fallacious for traditional CRT devices.
There is a developing emphasis on personalized remedies within the field of cardiac care. Tailoring CRT interventions to the person affected's desires, based totally on factors consisting of genetics, comorbidities, and lifestyle, is gaining prominence. This technique is improving remedy outcomes and patient pride. The worldwide enlargement of healthcare infrastructure, specifically in rising economies, is presenting multiplied entry to advanced cardiac treatment options like CRT. As healthcare structures increase and emerge as more available, the demand for sophisticated cardiac interventions is predicted to push upward, in addition to boosting the CRT market. The reimbursement panorama performs a vital function in shaping market traits. Changes in healthcare repayment regulations, both at local and national degrees, can have an impact on the adoption of CRT devices. Favorable repayment eventualities can inspire healthcare vendors and sufferers to choose these advanced cures.
The CRT market is characterized by means of extreme opposition among key players. Companies are investing in studies and development to stay at the leading edge of innovation, striving to offer contemporary technology and gain a competitive area. This competition is fostering improvements in CRT gadgets and contributing to a market boom. With a growing preference for minimally invasive processes, there's a growing cognizance of non-invasive alternatives to conventional CRT. This consists of exploring external devices, wearable technologies, and other tactics that limit the want for invasive implantation while delivering powerful cardiac resynchronization.
Cardiac Resynchronization Therapy Market Highlights:
Global Cardiac Resynchronization Therapy Market Overview
Cardiac Resynchronization Therapy Market Size was valued at USD 4.99 Billion in 2023. The Global Cardiac Resynchronization Therapy industry is projected to grow from USD 5.22 Billion in 2024 to USD 7.43 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5.15% during the forecast period (2024 - 2032).
The increasing prevalence rate of cardiac diseases followed by, rising demand for invasive techniques, fueling market growth.
Cardiac disease is the leading cause of death for US population. Biotronik announced FDA approval of the world's first MRI-safe pacemaker with a subcutaneous defibrillator (S-ICD) lead for patients with heart failure in February 2024.
This new device, called the Biotronik Innovo MRI Safe System with Innovo MRI Subcutaneous ICD, could improve patient care by allowing for more frequent MRI scans without compromising safety. Cardiac diseases are most common in low- and middle-income countries and these disorders. Increasing awareness of cardiac resynchronization therapy (CRT) devices and favorable government regulation towards reimbursement scenario.
Cardiac Resynchronization Therapy (CRT) Market Drivers
- Increasing sedentary lifestyle – leading a sedentary lifestyle is a major public health issue, it is increasingly spreading in many nations irrespective of being linked to various type of chronic health conditions.
- Rising geriatric population
- Rising investments in the healthcare sector – In 2016, the expenditure of US on medical and health research and development (R&D) was around USD 171.8 billion, and US healthcare expenditure was USD 3482.2 billion.
- Increasing technologically advances in medical devices
- The rising number of surgical procedures
- The growing number of intensive care units
Cardiac Resynchronization Therapy (CRT) Market Restraints
- The high cost of therapy – In 2017, the initial cost of cardiac resynchronization therapy pacemaker (CRT-P) is USD 16,218.44 and USD 36,263.73 of cardiac resynchronization therapy defibrillator (CRT-D).
Cardiac Resynchronization Therapy (CRT) Market Segment Insights
Cardiac Resynchronization Therapy Application Insights
- Intraventricular dyssynchrony: This segment holds the largest share because majority of the patients are estimated to be suffering from intraventricular dyssynchrony due to heart failure and left bundle branch block.
- Interventricular (V-V) dyssynchrony: This segment holds the second largest segment of the cardiac resynchronization therapy market. V-V dyssynchrony occurs when there is interruption or delay between the right ventricle and left ventricle activation.
- Atrioventricular (A-V) dyssynchrony: The A-V dyssynchrony occurs due to atrial and ventricle contraction, which can result in shortened ventricle filling time and mispositioning of atrial contraction.
Cardiac Resynchronization Therapy Type Insights
- Cardiac resynchronization therapy pacemaker (CRT-P): This segment holds the highest cardiac resynchronization therapy market share. In 2019, a study showed patients using CRT-P had 33% of death rate out of 135 patients.
- Cardiac resynchronization therapy defibrillator (CRT-D): This segment is not as popular as CRT-D, the study shows patients using this therapy has more risk of heart failure as in year 2019, out of 135 non-ischemic cardiomyopathy patients 43% of people died.
Cardiac Resynchronization Therapy End-User Insights
- Hospitals: The largest segment, hospitals and clinics are usually the primary points for diagnosis, treatment, and rehabilitation of individuals afflicted with cardiac resynchronization therapy. Growing awareness and increasing efficiency of musculoskeletal system disorder treatment are projected to drive the growth of this segment during the forecast period.
- Cardiac Specialty Centers: A small segment, these centers provide immediate pain relief and rudimentary surgical care.
- Academic and Research Organizations: This segment includes home care and senior citizen centers.
Cardiac Resynchronization Therapy Regional Insights
- Americas: The largest regional cardiac resynchronization therapy market, the prevalence of cardiac resynchronization therapy is high in the Americas; the region also has a well-established healthcare industry.
- Europe: An increasing geriatric population is leading to a rise in the number of musculoskeletal system disorder cases.
- Asia-Pacific: The fastest-growing regional cardiac resynchronization therapy market, Asia-Pacific is seeing a surge in the number of people afflicted with cardiac resynchronization therapy due to bad posture brought on by lifestyle changes, aging, and genetic predisposition. However, with the growing CRT market, particularly in Asia, it is likely that these companies are continuing to develop and refine their CRT offerings.
- Middle East & Africa: The smallest market due to limited healthcare infrastructure and a very young population.
Cardiac Resynchronization Therapy (CRT) Market Top Key Players
- Medtronic
- Abbott
- BIOTRONIK, Inc.
- Boston Scientific Corporation
- Lepu Medical Technology Co., Ltd.
- Medico S.p.A.
- MicroPort Scientific Corporation
- Shree Pacetronix Ltd
- Others
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report